Welcome to our dedicated page for Icecure Medical Ltd. SEC filings (Ticker: ICCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IceCure Medical Ltd. (Nasdaq: ICCM) is a foreign private issuer that files reports with the U.S. Securities and Exchange Commission (SEC) in connection with its liquid-nitrogen-based cryoablation systems for tumor destruction. On this page, you can review IceCure’s SEC filings, including current reports on Form 6-K that furnish press releases about regulatory milestones, clinical data, commercial progress, and corporate actions.
IceCure’s Form 6-K filings often incorporate press releases by reference into its registration statements on Form F-3 and Form S-8. These filings cover topics such as U.S. Food and Drug Administration (FDA) marketing authorization for the ProSense® Cryoablation System in low-risk breast cancer for women aged 70 and above, regulatory approvals for ProSense® in Switzerland and other markets, notices of patent allowance for technologies like cryogen flow control related to the next-generation XSense™ system, and financial and operational results for specified reporting periods.
Filings also document corporate developments, including changes in management roles and Nasdaq notifications regarding minimum bid price compliance. By reviewing these documents, investors can see how IceCure describes its minimally invasive cryoablation technology, its primary focus areas in breast, kidney, bone, and lung cancer, and the regulatory and commercial steps it reports taking to expand use of ProSense® and XSense™.
Stock Titan’s SEC filings page presents IceCure’s submissions as they are made available on EDGAR and enhances accessibility with AI-powered summaries. These summaries are designed to highlight key points from lengthy documents, such as the nature of a regulatory authorization, the scope of a patent allowance, or the main elements of a financial update. Users can quickly identify filings related to clinical milestones, regulatory approvals, capital markets activity, and other material events disclosed by IceCure Medical Ltd.
IceCure Medical Ltd. (ICCM) submitted a Form 6-K to furnish a press release covering its financial and operational results for the nine months ended September 30, 2025. The press release, dated November 19, 2025 and titled “IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025,” is attached as Exhibit 99.1.
Most of this press release, excluding its third, fourth, and fifth paragraphs, is incorporated by reference into IceCure’s existing registration statements on Form F-3 and Form S-8. This means the disclosed information becomes part of those registration statements from the date of this 6-K submission, unless later filings replace it.
IceCure Medical Ltd. reported that it issued a press release announcing that its ProSense® cryoablation system received regulatory approval in Switzerland for use in treating breast, lung, liver, and kidney cancer. The press release, dated November 18, 2025, is furnished as an exhibit to this report. Most of the press release (excluding its second paragraph) is also incorporated by reference into IceCure’s existing shelf and employee equity compensation registration statements on Forms F-3 and S-8, making the Swiss approval disclosure part of those offering documents.
IceCure Medical Ltd. (ICCM) furnished a Form 6-K noting it issued a press release titled “IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification.” The press release is attached as Exhibit 99.1.
The submission states this report is incorporated by reference into the company’s existing registration statements on Form F-3 (Nos. 333-258660, 333-267272, 333-290046) and Form S-8 (Nos. 333-270982, 333-264578, 333-262620, 333-281587).
IceCure Medical Ltd. (ICCM) announced a management change. On November 5, 2025, the Board promoted Mr. Shay Levav, previously Vice President of Regulatory and Quality Assurance and Clinical Applications since September 2020, to Chief Operating Officer.
The company also furnished a press release on November 10, 2025, and incorporated it by reference into its existing Form F-3 and Form S-8 registration statements.
IceCure Medical (ICCM) furnished a Form 6-K announcing it issued a press release titled “IceCure’s Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival.”
The press release (Exhibit 99.1) is incorporated by reference into the Company’s Registration Statements on Form F-3 (Nos. 333-258660, 333-267272, 333-290046) and Form S-8 (Nos. 333-270982, 333-264578, 333-262620, 333-281587).
IceCure Medical reported an executive change, delivering a notice of termination to Vice President of Operations and Services Galit Malik, with her employment ending on January 15, 2026. The company stated the termination was not related to any disagreement regarding operations, policies, or practices.
The report is furnished on Form 6-K and is incorporated by reference into IceCure Medical’s existing Form F-3 and Form S-8 registration statements.
IceCure Medical Ltd. reports that the U.S. FDA has granted marketing authorization for its ProSense® cryoablation system to treat low-risk breast cancer in women aged 70 and above. The company furnished two press releases on this authorization, highlighting it as a significant development in providing women with breast cancer a minimally invasive care option. Portions of these press releases are also incorporated by reference into several of IceCure's existing Form F-3 and Form S-8 registration statements.
IceCure Medical Ltd. filed a Form 6-K to furnish a press release dated September 30, 2025 about its ProSense® system’s presence at the European Society of Breast Imaging Congress 2025. The release highlights "unlocking de-escalation of care in breast cancer" and positive results from five independent studies. Most of the press release (excluding its second paragraph) is incorporated by reference into IceCure’s existing Form F-3 and Form S-8 registration statements, meaning that disclosure becomes part of those registration documents going forward unless later superseded.
IceCure Medical Ltd. submitted a Form 6-K reporting that it issued a press release on September 22, 2025 titled “IceCure’s ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented.” The press release, excluding its second paragraph, is attached as an exhibit and describes positive clinical results for the company’s ProSense cryoablation technology from four independent studies presented at the CIRSE 2025 annual meeting. The company is also incorporating this press release by reference into several of its existing Form F-3 and Form S-8 registration statements.
IceCure Medical Ltd. filed a Form 6-K to furnish a press release announcing that it was granted a notice of allowance for a U.S. patent covering its next generation XSense™ cryoprobes. The press release, dated September 18, 2025, is attached as Exhibit 99.1.
The filing also states that the first and third paragraphs of the press release, along with its “Forward Looking Statements” section, are incorporated by reference into IceCure’s existing registration statements on Form F-3 and Form S-8 in the United States, making this information part of those registration documents from the date of this submission.